PARP inhibition in BRCA-mutated cancer: improved survival for ovarian, breast, pancreatic and prostate cancer patients
- Submitting institution
-
Institute of Cancer Research: Royal Cancer Hospital (The)
- Unit of assessment
- 5 - Biological Sciences
- Summary impact type
- Technological
- Request cross-referral to
- -
- Is this case study continued from a case study submitted in 2014?
- No
- Underpinning research subjects
-
- Biochemistry And Cell Biology
- Clinical Sciences
- Oncology And Carcinogenesis
3. References to the research
5. Sources to corroborate the impact
Additional contextual information
Grant funding
| Grant number |
Value of grant |
| BBC024X (internal) |
£30,872,915 |
| CTR-Q3-Y1 |
£5,900,000 |
| CTR-Q3-Y2 |
£23,200,000 |
| MRC103X (internal) |
£233,620 |
| CRC369X (internal) |
£176,524 |
| IS-BRC-1215-20021 |
£43,074,315 |
| ACRF 02/03 |
£0 |
| SUC001X (internal) |
£1,066,784 |
| C347/A13907 |
£222,788 |
| C347/A8363 |
£2,073,409 |
| C347/A14276 |
£2,459,598 |
| C347/A24439 |
£2,042,986 |
| None given |
£530,886 |
| CTR-Q4 |
£39,327,814 |
- Countries
-
- US
- Austria
- Belgium
- Bulgaria
- Croatia
- Cyprus
- Czechia
- Denmark
- Estonia
- Finland
- France
- Germany
- Greece
- Hungary
- Ireland
- Italy
- Latvia
- Lithuania
- Luxembourg
- Malta
- Netherlands
- Poland
- Portugal
- Romania
- Slovakia
- Slovenia
- Spain
- Sweden
- Iceland
- Liechtenstein
- Norway
- UK
- Canada
- Japan
- Brazil
- China
- Formal partners
-
- Funding programmes
-
- Breast Cancer Now (previously Breakthrough Breast Cancer) Centre Core Grant 2003 to 2010
- Breast Cancer Now (previously Breakthrough Breast Cancer) Centre Core Grant 2010 to 2011
- Breast Cancer Now (previously Breakthrough Breast Cancer) Centre Core Grant 2011 to 2015
- Medical Research Council: Identification and development of synthetic lethal strategies and predictive biomarkers for therapy for MMR Deficient Colorectal Cancer
- Cancer Research UK: Sensitivity to PARP Inhibition mediated by PTEN deficiency: investigating a novel therapeutic approach
- The National Institute for Health Research Biomedical Research Centre at The Royal Marsden and The Institute of Cancer Research (2017)
- Breast Cancer Now (previously Breakthrough Breast Cancer) Avon Clinical Fellow
- Stand Up To Cancer: An Integrated Approach to Targeting Breast Cancer
- Cancer Research UK: Use of mouse models for identification and functional validation of mutated genes contributing to BRCA1/2 tumourigenesis
- Cancer Research UK: Cancer Susceptibility Genes (2008)
- Cancer Research UK: Cancer Susceptibility Genes (2012)
- Cancer Research UK: Cancer Susceptibility Genes (2017)
- High-throughput identification and evaluation of new breast cancer genes from GWAS.
- Breast Cancer Now (previously Breakthrough Breast Cancer) Centre Core Grant 2015 to 2021
- Global research identifiers
-
- grid.458394.7
- grid.420006.0
- grid.11485.39
- grid.451056.3
- grid.430427.6
- grid.431143.0
- Name of funders
-
- Breast Cancer Now (previously Breakthrough Breast Cancer)
- Medical Research Council
- Cancer Research UK (previously Cancer Research Campaign)
- National Institute for Health Research
- Stand Up To Cancer (part of the Entertainment Industry Foundation)
- National Health and Medical Research Council of Australia
- Researcher ORCIDs
-
- 0000-0003-1446-7878
- 0000-0002-3226-0515
- 0000-0001-8715-2901
- 0000-0003-3313-3857
